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SUMMARY
' Ihe 
scope of this thesis is rel ief of unnecessary suff-ering of sequelae of cancer ancl i ts
chernotherapeutic trei l tment
In chapter 2 zrn overview is given of shortcomin-us and perpectives of some prevalent
issues in support ive and pal l iat ive care in cancer and cancer chemotherapy: sorne of which
have deleterious etÍects on quali ty of l i Í 'e. Emphasis has been put on cancer induced cachexia,
elderly patients with cancer, carcinoid turnols, and integri ty of epithel ial cel l  sr"rrfaces af ler
chemotherapy.
In chapter 3 the efÍèct of age on decisions afïect ing diagnosis and treatment of ovarian
carlcer are reviewed. Almost half  of al l  ovarian catlcers occur in wonren or,er 6-5 years old.
ancl this age group ofien presents with more advanced cl isease. Diagnostic and theraper-rt ic
approaches to elderly wornen appear less intensive tharr in their younger counterparts. There
i. tre l1o ob.iect ive data support ing such an uncler-rnanagement. On the contrary. every patient.
irrespective of age. deserves accuÍate cl ia-enostic procedures and an optimal treatment. The
flrst clroice of treatment for advancecl ovarian cancer in elderly women is l ts in y()unger'
patients. adequate stagin.c of the disease by laparotomy with rnaximal surgicul debulking.
fbl lowed by cornbination chetrotherapy.
In chapter 4 a new in-vitro assÍ.ry of chemotherapy induced nrucosit is is clescribed.
Unt i l  now a l l  rnucc ls i t is  scor ing systerns were based on apparant  c l tanges of  n . lLrcos i t .
subjective complaints and functiortal inrpairment. These scoring syste tns are sLrb.ject i 'v 'e ancl
consequet r t ly  harnper  adequate eva luat ion and conrpar ison of  prevent ive s t ru teg ies.  In  th is
stLrdy inclucl ing I I  patients receiving high-dose chernotlrerapy fbl lowecl by reinfusion of
per iphera l  hu 'matopoie t ic  b lood s tenr  ce l ls  (PBSC).  pr ior  to  and twice week ly  a Í ter  h igh-
dose chemotherapy mLlcosa was eva luated.  Cl in ica l ly .  nrucos i t is  was suored accord ing to
the general lv Lrsed WHO toxicity 
.urading. The new. ir t-r,  i t ro i .rsse ssnlcnts of the nrLrcosa
included an oral washing and a buccal smear. In the oral washing the percentage l ' iable
epi the l ia l  ce l ls  was determined by t rypan b lue dye exc l i rs ion and leukocytes were counted
by f l i rorescence microscopy aÍ ier incubation with acridine urange. Maturi ty of buccal cel ls
was i issessed by s ta in ing buccal  snre iu 's  for  nrorphology accorc l ing to  Papanico laou.
Furthernrore. blood ler-rkocyte levels w'ere detennined. Eight healthy voluttteers serr,ecl as
controls. In the contrut ls the niezrn percentage of viable oral epithel ial cel ls was stable. wheleas
in patients af iel high-dose chernotherapy an increase wirs obse'rved. which was signif lcant
aÍ ier day 7 contpat 'ed to pretreatment. ln adcl i t ion. in the buccal srnears a shif i  from mature
to  imlnature ep i the l ia l  ce l ls  was noted.  Ora l  leukocyte leve ls  were c lose ly  cor re la ted wi th
the bloocl leukocyte counts. The WHO score Íbl lowed the results of this new system with
some delay.  The observed increase of  v iab le  ora l  ep i the l ia l  ce l ls  a f ier  chenio therapy is
probably the result of a desquanration of the upper oral n.rr.rcosa l yer. with a shif i  f i 'ont
ntature to nlore inrmature cel ls. These data can be qr.ranti tated and therefirre this assay nray
be usefu l  in  s tud ies a inred i t t  prevent ion o f  lnucos i t is .
The results of a pl iase-l  study with recornbinant Transfbrni ing-Glowth-Factor B3 (TGF-
03;  GCP.166l4)  nrouthwashes a i rned at  mucos i t is  prevent ion.  in  which the new assay was
applied, are reported in chapter 5. The primary aim of this phase-l study was to establ ish
the safety and tolerabi l i ty of the TGF-P3 mouthwashes. Especial ly local ef ' fects of the drLrg
were analyzed with assessment of mucosit is with objective ancl subjective nieasurements.
Eleven breast cancer patients receiving two dif fèrent. rni ldly stomatotoxic chemotherapy
re-uir-nens were included. TGF-B3 mouthwashes were given q.i .d. for Í i rur cousecutive days
start ing one day belore chemotherapy, and were well  tolerated. The nraxirnal TGF-83 dose
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in this study (100 ptg/rnl-) considerably exceeds the rnaxirnal topical appl ied dose used irr
aninrals. which in turn exceecled the dose showinc already preventive effècts in animals.
That. together with the fact that 100 prg/ml- TGF-P3 appeared the rnaximal fèasible dose
with respect to pharmacological nrarnuf 'acturin-9, was the reason that in this phase-l study no
attempts have beert made to rcach a maxirnal tolerable dose. Cl inical ly, mucclsit is incidence
and severity were as expected. The percenta-qe of viable oral epithel ial cel ls was stable in
one patient Í- ' rolrp and in the other sroup un increase was observed. This dif ference might be
expla ined by d i Í terent  leve ls  o f  s tumatotox ic i ty  o f  chernotherapy schedules or  f rorn
dissimilari ty o1-t inie elapsed after previous courses of chernotherapy. The rnorphology of
buccal cel ls showed a transient shif ï  from mzrture to ir lmature cel ls in the f- irst wc'ek. possibly
suggest ing a  prevent ive e t fec t  o f  TGF-B3.  Nei ther  systemic  absorpt ion o f  TGF-p3 nor
developr-nent of TGF-p3-antibodies was observecl.  I t  was concluded that mouthwashes with
TGF-83 are well- tolerated and deserve f irr ther study in preventing chemotherapy induced
rnucos i t is .
Chapter 6 describes a randorrt ized mult icentre study evaluating efÍ icacy. saÍèty and
tolerabi l i ty o1-2 and -5 rr ig tropisetron. adrninistered intravertously on day I and oral ly days
2-6,  in  prevcnt ion o f  t rausea and vot t r i t ing indr - rced by low-dose c isp la t in  or  non-c isp la t i r r
containing chernotlrerapy in l-52 chernotherapy-naive cancer patients. Thcre was i t  better
to ta l  cont ro l  (no events)  o Í 'acute vont i t ing (day l  )  in  the -5  r rg  (73%) than in  the 2  rng r r roup
(55tá). and of total ur ma.jor control (  l -2 events) of acute vomit ing (84(/c and -59% respecti-
v e l y ) . T o t a l  c u r r t r o [  ( <  l 5 m i n ) o f a c u t e n a u s e a w a s o b t a i n e d i n - 5 1 % o t t h e 2 n r g a n r l i n T 0 / r
o f  t l rc  -5  nrg group.  to ta l  or  nra. jorcont ro l  (> l -5  nr in  -  4  h)of  rcute  n i lusea in l3% tn t l9 l ' / r
respcctively. No diÍ ferences were observed l irr  total control o1'de laired (days 2-6) nausea ur
vorl i t ing and t irr  the overal l  outcorle of nausea. Less vornit ing (days l-6) occLrrred in the -5
mg than in the 2 nrg group. Efl icacy rates ranged widely betwecn chernotherapy regimens.
inclependent of the trclpisetron closc grl)ups. Mrlre l teaclache \\ / i . ls experiencecl in the' -5 rng
sroup.  I t  was conc luded that  oncc da i ly  5  mu t rop iset ron is  super ior  to  2  mg f i r r  prevent ior r
o f  acute vomi t in- r r  anc l  nausea induced by low-dose c isp la t in  or  non-c isp la t in  cherr io therapy
re-eirnerts. but causes tnore hrraditche.
In  chapter  7  an e xa lnp lc  o f  cornb in ing c l in ica l  obserr ,a t ions wi th  laboratory  techniqr - res
to  tes t  a  hvpothes is  a in ied at  ga in in l  ins ight  in  pathophys io lou ica l  nrechanisr .ns is  presentec l .
Rein fus ion o l  PBSCI or  bone marrow is  o f ten fo l lowed by l ' lush in-u.  dyspnea and chest
t ightness,  nausea and d iar rhea,  and abdorr t ina l  c ramps.  Espec ia l ly  the pronrpt  l ' l r - rsh ing,
conrbined wit l i  the otrscrl 'at ion that sonre oÍ '  t l rcse sicle eÍÍ 'ects can be prevented by the
se lect ive -5-HT,  r 'ecepto l  n tagr tn is t  ondanset ron.  led to  the assunrpt ion that  re in fus ion of
PBSC orbone Inarrow is coincided with infusir ln of Í ' ree serotonin. Therefore. in 25 patients
with various sol id tunrors. receiving a total oÍ '-10 reint 'usinns of PtsSC and/or bone nrarrow
afier ntyeloablat ive chetnotherapy. parameters of serotonin nretabol isrr l  were assessed beÍi l re
and afier rcinf irsion. Tlte serotonin content o1-platelets increased signit icantly at ier reinf irsion,
whereas the 24 h ur inary  excret ion o f  5-hydroxy indole  acet ic  ac id  ( -5-HIAA)  and seroton in
were not aÍfected. In l7 patients. the serotclrr in levels in the bags containing PBSC were
nreasured and. conrbined with the total reinf irsecl volume. the arnount of serotonin coinciding
reinfusion coulcl be calcutated. The reinfusion occurred with a substantial serotonin load of
about 1000 ptrnol.  which inducecl etn increase in total circulat ing serotonin pool of about
100%. We concluded that side effects coinciding reinfusion of PBSC or bone marrow can,
at least part ial ly, be attr ibutecl to concomitant reinfusi<ln of serotonin, ancl t l -rereÍ i l re the use
of -5-HT, receptors antirgonists as premedicrrt ion f irr  this ploceclure are 
. just i f led.
1 3 3
( l  r r e t , r n n  I l
The last part of the thesis fbcusses on .symptom rel ief in carcinoid patients.
Chapter 8 describes the eff 'ects of the -5-HT: antagonist ondansetlon on gastr ic enrptying
and cln upper gastrointestinal symptoms in carcinoid patients. Patients with a metastasized
carc ino id  o f ten exh ib i t  symptoms such as d iar rhea and f lush ing,  but  in  addi t ion,  they
sonlet imes complain about Lrpper gastrointestinal syrnptorns. especial ly nausea. Reduction
of symptoms rnight be achieved by inhibit ion of the production or release of serotonin, as
well  as by reduction of i ts effects. Recently, new information became avai lable about
serotonin receptors and their Íunction in the cl igestive tract. Furthermore, highly selective
serotonin (5-HTr) rcceptor antrgonists such as ondansetron have been developed, which
appeared efïèct ive in preventing chemotherapy indirced nausea and vomit ing. We studied
the efÍect of ondansetron on 
,qastr ic ernptying nreasured by applied potential tornography
and.  i f  app l icab le ,  on uppeÍ '  gast ro in test ina l  symptoms in  e leven carc ino id  pat ients .  The
mean gast r ic  l ra l f  enrpty ing t ime.  measured by appl ied potent ia l  tomography.  increased
after treatment with ondansetron. irnpl icat ing a possible slower gastr ic ernptying. Nausea
was reportcd by 4 patients and improved in 3 of them during ondansetron. whereas cl iarrhea
improved in al l  6 patients report in-u diarrhea. Flushing was not afÍècted. As expected. no
changes in serotonin in platelets and urinary excretion of -5-HIAA levels u,ere observed,
since ondansetron only blocks -5-HTr receptors. without inf luencin-t serotonin release. l t
was concluded that ondansetrr)n can inrprove gastrointestinal synrptonis in carcinoid patients
ur rd  poss ib ly  s lows Í Ias t r ic  ernpty ing.
In chapter 9 the results of a rnult i-centre study are reported. evaluating the effect of the
long-acting sonratostat in analogLre lanreotide prolonred release (PR) in patients with castroin-
test inal neuroendocrine tumors, on hormone related symptomatology, tumor markers and
tunxrr size and tolerabi l i ty. In acldit ion. this stucly is t l re f irst study in this patient categorie
that adresses the eftècts of sornatostat in analogue treatment on quali ty of l i fè. In the past,
son'rutost:.r t in a alo-gues ucl 'r  as octreotide appeared eflèct ive in arneloriat ion of symptoms
in t l rese pat ients .  A migor  d isac lvantage of  oc t reot ide is  that  i t  must  be admin is tered
subcutaneously two or three t imes a day. Treatnrent with lanreotide PR can be adnrinistered
by i r r t ramusc:u lar  i r r jec t ion e \ /ery  two weeks.  and e l i rn inates the nrLr l t ip le  da i ly  in jec t ions.
The s tudy inc luded 5-5 pat ients  wi th  substant ia l  da i ly  symtoms.  48 wi th  carc ino id  turxors .  6
with gastr inomas and I with VIPorna. Symptornatic irnprovement wits observed in 387c of
evaf uable patients with carcinoid tumor. in6JC/a of patients with 
-uastr inoma, and the VIPoma
patient. Tuntor markers were evaluable in 45 patients. Normalization occurred in 2 patients
(5c/ r .  I  gast r i r roma nd the VIPorna) .  l9  pat ients  (42%l  exh ib i ted a  reduct ion,  l9  pat ients
(421r)  exh ib i ted no change and tumur  rnarkers  rose in  5  pat ier r ts  ( l l7c , ) .  Two of  the 3 l
eva luable  carc ino ic l  pat ients  showed a s icn i t icant  tLrmor  reduct ion.  2-5 pat ients  remained
stahle and 4 patients (-3 carcinoid. I  gastr inoma) experienced progression (>-507c;. Quali ty
of l i fè i issessnrents af ier I  morrth showecl irnprovernents in emotional and cognit ive function
as well  as dini inished Íat igue. sleeping disorders and diarrhea. Eight out of 30 evaluable
pa t i en t s  deve loped  ga l l s t ones .  We  conc luded  tha t  l an reo t i de  PR i s  a  we l l - t o l e ra ted
sonratosta t in  analogue wi th  s ign i f icant  c l in ica l .  b iochemica l  and ant i - tumor  e f fec ts .  and a
signif icant inrpnn'ement of qual i ty of l i f -e in patients with neuroendocrine tumors.
In  chapter  l0  a  case h is tory  is  presented.  which dc-monst ra tes that  a  metastast ized
carcinoid tunlor is capable to induce an extraordinary symptom cornplex. due tcl  the producti-
on and release clf  various hormorre.s. In addit ion to conventional treatnrent f i rr  carcinoid
cl isease. patients obviously can benefi t  of more selective clrug treatrnent. which is based on
the biochenrical secretion profl le oÍ ' the tLlmor.
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